Nkarta, Inc. (NKTX) Form 8-K — May 12, 2026
Nkarta, Inc. reported a net loss of $27.8 million, or $0.37 per share, for the first quarter of 2026. This loss is in line with the company's ongoing clinical development and operational expenses. The company's cash, cash equivalents, restricted cash, and investments stood at $266.7 million as of March 31, 2026, which is expected to fund operations into 2029.
Key figures
- Eps
- -0.37
- Eps Beat
- 0
- Revenue
- 0
- Guidance
- Nkarta expects its current cash and cash equivalents to fund its current operating plan into 2029.
- Net Income
- -27,832
- Total Debt
- 86,213
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 372,073
- Cash Position
- 266,739
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 74,257,973
- G&A expenses
- 5,888
- R&D expenses
- 24,988
- Cash, cash equivalents, restricted cash and investments
- 266,739
Price after filing
1 day: -6.7%7 days: -18.3%30 days: -25.0%
Close on the filing date to close N calendar days later (from $3.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.